Advanced Proteome’s vision is to advance the field of protein-site targeting to deliver more effective and personalized cancer therapies faster, accelerate improvement in survival rates, while creating value for all stakeholders. The company plans to fulfill this vision by boldly creating protein therapeutics that carry multiple entities targeted for specific cancer cells. Such protein conjugates are constructed by attaching each entity to its own specific site on the protein surface to give homogeneous, pure product. To develop such products with multiple properties borne by a single agent, that can pass muster with regulatory agencies, Advanced Proteome has developed powerful site-specific conjugation methods. These methods facilitate the attachment of organic chemical entities such as drugs to specific sites on the carrier protein.